More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...
Higher rates of mortality seen among patients with systemic lupus erythematosus, with disparities by sex, race and ethnicity, and region.
Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results